40
Participants
Start Date
January 5, 2022
Primary Completion Date
August 22, 2024
Study Completion Date
February 20, 2025
Lenalidomide
Maintenance lenalidomide, starting at 5 mg a day for 21 days of a 28-day cycle, will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the participant reaches 12 months post CAR T-cell infusion and continues free of progression
bb2121
Participants receive infusion of BCMA CAR T-cells at a target dose of 450 x 10\^6 cells.
Cyclophosphamide
300 mg/m\^2/day for 3 consecutive days prior to the CAR T infusion
Fludarabine
30 mg/m\^2/day or 3 consecutive days prior to the CAR T infusion
leukapheresis
Placement of central line catheter and leukapheresis
Mount Sinai Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Cancer Center, Buffalo
University of Pennsylvania Hospital Center, Philadelphia
University of Virginia, Charlottesville
Duke University Medical Center, Durham
H. Lee Moffitt Cancer Center, Tampa
Medical College of Wisconsin, Milwaukee
University of Wisconsin Hospitals and Clinics, Madison
Loyola University Medical Center, Maywood
Baylor College and Medicine, Houston
City of Hope National Medical Center, Duarte
University of California, San Francisco, San Francisco
Stanford Hospital and Clinics, Palo Alto
Beth Israel Deaconess Medical Center, Boston
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Blood and Marrow Transplant Clinical Trials Network
NETWORK
National Cancer Institute (NCI)
NIH
National Marrow Donor Program
OTHER
Celgene a wholly owned subsidiary of BMS
UNKNOWN
Marcelo Pasquini, MD
OTHER